Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 3/20 | 0.41 |
| ▸ | MC1R | Q01726 | 3/20 | 0.41 |
| ▸ | MC3R | P41968 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830944 | 0.84 | CYP2C19 (0.56) | CYP1A2CYP2A6NPC1RAB9ACYP2C19 | |
| SCHEMBL652140 | 0.82 | TDP1 (0.47) | CYP1A2CYP2C19CYP2C9FFAR1AKR1B1 | |
| SCHEMBL7915037 | 0.79 | MAPK1 (0.65) | MC5RMAPK1CYP1A2CYP2A6CYP2C19 | |
| SCHEMBL31509450 | 0.79 | MAPK1 (0.65) | MC5RMAPK1CYP1A2CYP2A6CYP2C19 | |
| SCHEMBL932837 | 0.77 | MC5R (0.63) | MC5RMAPK1CYP1A2CYP2A6CYP2C19 | |
| SCHEMBL5778428 | 0.75 | MC5R (0.59) | MC5RMAPK1CYP1A2CYP2A6CYP2C19 | |
| SCHEMBL932836 | 0.75 | MAPK1 (0.47) | MC5RMAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL49863 | 0.75 | CYP1A2 (0.69) | MC5RMAPK1CYP1A2CYP2A6CYP2C19 | |
| SCHEMBL7415238 | 0.73 | ALDH1A1 (0.46) | MAPK1CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL5252496 | 0.73 | CYP2C19 (0.50) | CYP1A2NPC1RAB9ACYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220193086-A1 | COMBINATION THERAPY | MEI PHARMA, INC. | 2022-06-23 | — | — | US | disclosed |
| US-11351176-B2 | Combination therapy | MEI PHARMA, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210000838-A1 | COMBINATION THERAPY | MEI PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3736291-A1 | ANTI-FCRH5 ANTIBODIES | Genentech, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200222415-A1 | COMBINATION THERAPY | MEI PHARMA, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200197403-A1 | COMBINATION THERAPY | MEI PHARMA, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190201409-A1 | COMBINATION THERAPY | MEI PHARMA, INC. | 2019-07-04 | — | — | US | disclosed |
| EP-2691384-B1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150265625-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9056852-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-5639781-A | PREVENT REABSORPTION OF BONE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0398373-B1 | Electrophotographic light-sensitive material | FUJI PHOTO FILM CO LTD (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-5178983-A | Binder resin | FUJI PHOTO FILM CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0398373-A1 | Electrophotographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1990-11-22 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193086-A1 | COMBINATION THERAPY | CD274, PDCD1, PDPK1 | MC5R 2523/4885MAPK1 172/4885CYP1A2 4532/4885 |
| US-20200197403-A1 | COMBINATION THERAPY | CD274, PDCD1, PDPK1 | MC5R 2523/4885MAPK1 172/4885CYP1A2 4532/4885 |
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | MC5R 2211/4885MAPK1 1937/4885CYP1A2 224/4885 |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | MC5R 2211/4885MAPK1 1937/4885CYP1A2 224/4885 |
| US-20200222415-A1 | COMBINATION THERAPY | CD209, BTK, CD47 | MC5R 1888/4885MAPK1 749/4885CYP1A2 4155/4885 |
| US-11351176-B2 | Combination therapy | CD209, BTK, CD47 | MC5R 1888/4885MAPK1 749/4885CYP1A2 4155/4885 |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | MC5R 2211/4885MAPK1 1937/4885CYP1A2 224/4885 |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | MC5R 2211/4885MAPK1 1937/4885CYP1A2 224/4885 |
| US-20150265625-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | MC5R 2211/4885MAPK1 1937/4885CYP1A2 224/4885 |
| US-20190201409-A1 | COMBINATION THERAPY | EZH2, BTK, BMI1 | MC5R 2705/4885MAPK1 1448/4885CYP1A2 3705/4885 |
| US-20210000838-A1 | COMBINATION THERAPY | BTK, SYK, PIK3C3 | MC5R 2695/4885MAPK1 949/4885CYP1A2 4502/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | MC5R 4830/4885MAPK1 2930/4885CYP1A2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.